Antisecretory and antigastrin effects of rioprostil in gastric fistula dogs

Laurence B. Katz, Thomas Genna, George H. Greeley, David A. Shriver

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This investigation examined the effect of rioprostil, a primary alcohol prostaglandin E1 analog, on betazole-stimulated gastric acid secretion and on basal and food-stimulated (postprandial) serum gastrin levels in gastric fistula dogs. Rioprostil inhibited betazolestimulated gastric acid secretion with an ED50 of 16 (10-24) μg/kg, intragastrically. A near-maximal gastric antisecretory dose (100 μg/kg, intragastrically) had no effect on basal serum gastrin levels but significantly attenuated the rapid rise in serum gastrin which follows feeding, a result different from that reported for other prostaglandin E1 analogs. A nonantisecretory dose of rioprostil (1.0 μg/kg, intragastrically) also attenuated the rise in postprandial serum gastrin. An antigastrin effect using a nonantisecretory dose of an antiulcer agent has not been reported previously and may indicate that rioprostil has a direct inhibitory effect on secretion of gastrin. The ability of rioprostil to inhibit gastric acid secretion and decrease postprandial peak serum gastrin levels, coupled with previously established cytoprotective efficacy, makes it an attractive clinical candidate for the treatment and prevention of peptic ulcer disease.

Original languageEnglish (US)
Pages (from-to)1268-1274
Number of pages7
JournalDigestive Diseases and Sciences
Volume32
Issue number11
DOIs
StatePublished - Nov 1987

Fingerprint

Rioprostil
Gastric Fistula
Gastrins
Dogs
Gastric Acid
Synthetic Prostaglandins
Serum
Alprostadil
Betazole
Peptic Ulcer
antigastrin
Stomach
Alcohols
Food

Keywords

  • fistula dogs
  • gastric acid
  • gastrin
  • prostaglandins
  • rioprostil

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Antisecretory and antigastrin effects of rioprostil in gastric fistula dogs. / Katz, Laurence B.; Genna, Thomas; Greeley, George H.; Shriver, David A.

In: Digestive Diseases and Sciences, Vol. 32, No. 11, 11.1987, p. 1268-1274.

Research output: Contribution to journalArticle

Katz, Laurence B. ; Genna, Thomas ; Greeley, George H. ; Shriver, David A. / Antisecretory and antigastrin effects of rioprostil in gastric fistula dogs. In: Digestive Diseases and Sciences. 1987 ; Vol. 32, No. 11. pp. 1268-1274.
@article{2cf551053cde48a39b2ef8f6c2a95e82,
title = "Antisecretory and antigastrin effects of rioprostil in gastric fistula dogs",
abstract = "This investigation examined the effect of rioprostil, a primary alcohol prostaglandin E1 analog, on betazole-stimulated gastric acid secretion and on basal and food-stimulated (postprandial) serum gastrin levels in gastric fistula dogs. Rioprostil inhibited betazolestimulated gastric acid secretion with an ED50 of 16 (10-24) μg/kg, intragastrically. A near-maximal gastric antisecretory dose (100 μg/kg, intragastrically) had no effect on basal serum gastrin levels but significantly attenuated the rapid rise in serum gastrin which follows feeding, a result different from that reported for other prostaglandin E1 analogs. A nonantisecretory dose of rioprostil (1.0 μg/kg, intragastrically) also attenuated the rise in postprandial serum gastrin. An antigastrin effect using a nonantisecretory dose of an antiulcer agent has not been reported previously and may indicate that rioprostil has a direct inhibitory effect on secretion of gastrin. The ability of rioprostil to inhibit gastric acid secretion and decrease postprandial peak serum gastrin levels, coupled with previously established cytoprotective efficacy, makes it an attractive clinical candidate for the treatment and prevention of peptic ulcer disease.",
keywords = "fistula dogs, gastric acid, gastrin, prostaglandins, rioprostil",
author = "Katz, {Laurence B.} and Thomas Genna and Greeley, {George H.} and Shriver, {David A.}",
year = "1987",
month = "11",
doi = "10.1007/BF01296377",
language = "English (US)",
volume = "32",
pages = "1268--1274",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Antisecretory and antigastrin effects of rioprostil in gastric fistula dogs

AU - Katz, Laurence B.

AU - Genna, Thomas

AU - Greeley, George H.

AU - Shriver, David A.

PY - 1987/11

Y1 - 1987/11

N2 - This investigation examined the effect of rioprostil, a primary alcohol prostaglandin E1 analog, on betazole-stimulated gastric acid secretion and on basal and food-stimulated (postprandial) serum gastrin levels in gastric fistula dogs. Rioprostil inhibited betazolestimulated gastric acid secretion with an ED50 of 16 (10-24) μg/kg, intragastrically. A near-maximal gastric antisecretory dose (100 μg/kg, intragastrically) had no effect on basal serum gastrin levels but significantly attenuated the rapid rise in serum gastrin which follows feeding, a result different from that reported for other prostaglandin E1 analogs. A nonantisecretory dose of rioprostil (1.0 μg/kg, intragastrically) also attenuated the rise in postprandial serum gastrin. An antigastrin effect using a nonantisecretory dose of an antiulcer agent has not been reported previously and may indicate that rioprostil has a direct inhibitory effect on secretion of gastrin. The ability of rioprostil to inhibit gastric acid secretion and decrease postprandial peak serum gastrin levels, coupled with previously established cytoprotective efficacy, makes it an attractive clinical candidate for the treatment and prevention of peptic ulcer disease.

AB - This investigation examined the effect of rioprostil, a primary alcohol prostaglandin E1 analog, on betazole-stimulated gastric acid secretion and on basal and food-stimulated (postprandial) serum gastrin levels in gastric fistula dogs. Rioprostil inhibited betazolestimulated gastric acid secretion with an ED50 of 16 (10-24) μg/kg, intragastrically. A near-maximal gastric antisecretory dose (100 μg/kg, intragastrically) had no effect on basal serum gastrin levels but significantly attenuated the rapid rise in serum gastrin which follows feeding, a result different from that reported for other prostaglandin E1 analogs. A nonantisecretory dose of rioprostil (1.0 μg/kg, intragastrically) also attenuated the rise in postprandial serum gastrin. An antigastrin effect using a nonantisecretory dose of an antiulcer agent has not been reported previously and may indicate that rioprostil has a direct inhibitory effect on secretion of gastrin. The ability of rioprostil to inhibit gastric acid secretion and decrease postprandial peak serum gastrin levels, coupled with previously established cytoprotective efficacy, makes it an attractive clinical candidate for the treatment and prevention of peptic ulcer disease.

KW - fistula dogs

KW - gastric acid

KW - gastrin

KW - prostaglandins

KW - rioprostil

UR - http://www.scopus.com/inward/record.url?scp=0023269952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023269952&partnerID=8YFLogxK

U2 - 10.1007/BF01296377

DO - 10.1007/BF01296377

M3 - Article

VL - 32

SP - 1268

EP - 1274

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 11

ER -